CF medicines
Revenue Exposure
Substantially all net product revenues come from CF medicines, making revenue highly concentrated in one franchise.
Relevance 98·Dependency 95·Confidence 98
Source evidence
“Substantially all our net product revenues have been derived from the sale of our CF medicines.”
TRIKAFTA/KAFTRIO
Revenue Exposure
2025 revenue growth primarily driven by continued strong TRIKAFTA/KAFTRIO demand; CF franchise is dominant revenue source.
Relevance 95·Dependency 90·Confidence 95
Source evidence
“primarily due to continued strong demand for TRIKAFTA/KAFTRIO as well as contributions from our launches of ALYFTREK, JOURNAVX and CASGEVY”
CF patients and payers
Customer Exposure
Revenue depends on CF patients (~75% of CF population treated) and reimbursement agreements across geographies.
Relevance 90·Dependency 85·Confidence 90
Source evidence
“are being used to treat nearly three quarters of the people with CF in the U.S., Europe, Australia, and Canada”
U.S. drug pricing and reimbursement regulation
Regulatory Exposure
Mandatory U.S. pricing initiatives could reduce Vertex product pricing and reimbursement
Relevance 90·Dependency 85·Confidence 95
Source evidence
“implementation of mandatory initiatives could result in reduced pricing and reimbursement for our products.”
Specialty pharmacies, specialty distributors, major wholesalers
Customer Exposure
A limited number of US specialty pharmacies, distributors and wholesalers account for the largest portion of total revenues.
Relevance 85·Dependency 80·Confidence 95
Source evidence
“which
account for the largest portion of our total revenues”
Ex-U.S. government reimbursement systems
Regulatory Exposure
Non-reimbursed products are largely inaccessible to ex-U.S. patients; reimbursement terms and delays directly affect ex-U.S. revenue
Relevance 85·Dependency 80·Confidence 90
Source evidence
“the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are generally unable to access prescription pharmaceutical products that are not reimbursed by their governments.”
Medicaid Drug Rebate Program
Regulatory Exposure
Medicaid rebate obligations are the most significant revenue-recognition estimate, with a $1,777.6M accrual balance at 12/31/2025.
Relevance 85·Dependency 75·Confidence 95
Source evidence
“Our most significant estimate relates to determining amounts due pursuant to the Medicaid Drug Rebate
Program”
Lonza operates a dedicated 130,000 sq ft New Hampshire facility for T1D cell therapy manufacture under a strategic agreement.
Relevance 85·Dependency 70·Confidence 94
Source evidence
“a strategic agreement with Lonza to support the manufacture of T1D
cell therapy product candidates”
US drug pricing laws (IRA, PDABs, MFN/GUARD)
Regulatory Exposure
US pricing/access governed by Medicare/Medicaid rules (ACA, IRA), PDABs, and potential MFN/GUARD Model pricing could reduce pricing and reimbursement.
Relevance 85·Dependency 70·Confidence 92
Source evidence
“initiatives by the U.S. government to impose most-favored-nation pricing on U.S. prescription drug prices in government programs, including the recently proposed GUARD Model by the CMS.”
CROs, CMOs, logistics providers
Supplier Dependency
Critical R&D, API manufacturing/finishing, and distribution depend on third parties that may not be replaceable timely or on reasonable terms.
Relevance 80·Dependency 75·Confidence 92
Source evidence
“we may not be able to replace such third party in a timely manner, on commercially reasonable terms, or at all.”
Newest CF medicine, launching and reimbursed across 12+ markets, contributing to 2025 revenue growth.
Relevance 80·Dependency 40·Confidence 90
Source evidence
“contributions from our launches of ALYFTREK, JOURNAVX and CASGEVY”
Payor rebates and government-mandated discounts
Revenue Exposure
Government, commercial, and private payor rebates/chargebacks materially reduce net product revenue and require significant estimates.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“We are required to make estimates for our product revenues related to government, commercial, and private payor
rebates, chargebacks, discounts and fees”
cGMP supplier qualification requirements
Supplier Dependency
Key component suppliers must be named in regulatory filings; qualifying new suppliers can cause significant delays
Relevance 75·Dependency 70·Confidence 90
Source evidence
“Suppliers of key components and materials must be named in the NDA or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required.”
Reimbursement and patient access agreements
Regulatory Exposure
Growth in patients taking medicines depends on new approvals and reimbursement agreements; royalty rate changes affected cost of sales.
Relevance 75·Dependency 65·Confidence 85
Source evidence
“We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements”
Government-owned or supported international customers
Customer Exposure
International government-owned/supported customers have annual reimbursement caps requiring free goods beyond limits, affecting revenue deferral.
Relevance 75·Dependency 65·Confidence 90
Source evidence
“We have also entered into annual contracts with government-owned and supported customers in international markets
that limit the amount of annual reimbursement we can receive for our products.”
Investor value partly depends on JOURNAVX acute pain commercial success and NaV1.8/NaV1.7 neuropathic pain programs in a highly competitive market.
Relevance 75·Dependency 40·Confidence 90
Source evidence
“A portion of the value attributed to our company by investors is based on the expected commercial success of JOURNAVX for acute pain”
cGMP manufacturing regulations
Regulatory Exposure
Company, CMOs, and corporate partners subject to cGMP and inspections; deficiencies could suspend manufacturing operations.
Relevance 70·Dependency 65·Confidence 88
Source evidence
“we and our CMOs and corporate partners are subject to cGMP, as well as comparable regulations in other jurisdictions.”
CASGEVY gene-therapy revenue recognized upon infusion and sold via ATCs or specialty channels, with distinct distribution arrangements in certain markets.
Relevance 65·Dependency 50·Confidence 90
Source evidence
“upon infusion of our gene-therapy products, including CASGEVY”
CASGEVY launch generated $115.8M in 2025 with 64 patient infusions; scaling depends on reimbursed access.
Relevance 65·Dependency 20·Confidence 95
Source evidence
“In 2025, we recorded $115.8 million of CASGEVY product revenues.”
US-China biotech trade restrictions
Geopolitical Exposure
Proposed legislation limiting use of select Chinese biotechnology equipment/services creates uncertainty for service providers and trade relations.
Relevance 60·Dependency 40·Confidence 85
Source evidence
“U.S. legislation has been introduced to limit certain U.S. biotechnology companies from using equipment or services from select Chinese biotechnology companies”
Alpine (povetacicept acquisition)
Cost Driver
The $5.0B Alpine acquisition was expensed as AIPR&D ($4.4B for povetacicept) in 2024 due to asset-acquisition accounting.
Relevance 60·Dependency 40·Confidence 93
Source evidence
“$4.4 billion of the fair
value attributed to povetacicept was expensed to AIPR&D in 2024.”
CASGEVY revenue depends on physician/patient/payor acceptance and complex manufacturing with significantly higher cost as % of revenue.
Relevance 60·Dependency 30·Confidence 88
Source evidence
“The future commercial success of CASGEVY depends on physicians, patients, or payors accepting it as medically useful, cost-effective, ethical, safe, and preferred”
SCD/TDT patients and payers
Revenue Exposure
CASGEVY revenue tied to reimbursed access (~90% of U.S. SCD/TDT patients) and patient infusion throughput.
Relevance 60·Dependency 25·Confidence 90
Source evidence
“approximately 90 percent of people with SCD or TDT in the U.S. have reimbursed access to CASGEVY”
Vertex Pharmaceuticals
Cost Driver
Cost of sales ratio affected by CF royalty rate, product mix, and network expansion/manufacturing process improvement investments.
Relevance 55·Dependency 50·Confidence 85
Source evidence
“partially offset by changes in our product mix, and investments in network expansion and manufacturing process improvements”
New Hampshire Lonza facility
Cost Driver
Lease payments for the dedicated T1D facility begin Q1 2026 and continue through the tenth anniversary of regulatory approval for commercial production.
Relevance 55·Dependency 50·Confidence 90
Source evidence
“Lease payments will begin in the first quarter of 2026 and continue
through the tenth anniversary of the facility's regulatory approval for commercial production.”
Massachusetts coastal facilities
Manufacturing Dependency
HQ and key logistics, laboratory, and manufacturing space sit in a coastal flood zone; catastrophic loss would seriously harm operations.
Relevance 55·Dependency 45·Confidence 90
Source evidence
“If any of our major facilities were to experience a catastrophic loss due to an earthquake, flood, severe storms, fire or similar event, our operations would be seriously harmed.”
JOURNAVX, newly approved non-opioid acute pain medicine, contributed to 2025 revenue growth; launch ongoing.
Relevance 55·Dependency 15·Confidence 90
Source evidence
“We are continuing our commercial launch of JOURNAVX for eligible adults.”